ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 0601 • ACR Convergence 2024

    Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib

    Peter C. Taylor1, Lihi Eder2, Yael Klionsky3, Fabian Proft4, Thomas Iyile5, Erin Mancl6, Priscila Magalhaes Reis Nakasato7, Xiaolan Ye8, Limei Zhou6 and Philip Mease9, 1University of Oxford, Oxford, United Kingdom, 2University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 3Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5AbbVie Inc., hyattsville, MD, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., Randolph, NJ, 8AbbVie Inc., Mettawa, IL, 9Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…
  • Abstract Number: 1040 • ACR Convergence 2024

    Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics

    Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Cathy Lee Ching9, Zineb Aouhab10, Swamy Venuturupalli11, Daniel Wallace12, rosalind Ramsey-Goldman13, Alfred Kim14, Maureen McMahon15, S. Sam Lim16, Kalpana Bhairavarasu17, Alexa Meara18 and Kenneth Kalunian19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9UMMC, Jackson, MS, 10Loyola University Medical Center, Oak Brook, IL, 11Attune Health, Beverly Hills, CA, 12Cedars Sinai Medical Center, Studio City, CA, 13Northwestern University, Chicago, IL, 14Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 15UCLA David Geffen School of Medicine, Los Angeles, CA, 16Emory University, Atlanta, GA, 17Baylor College of Medicine, Sugar Land, TX, 18The Ohio State University Wexner Medical Center, COLUMBUS, OH, 19University of California San Diego, La Jolla, CA

    Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
  • Abstract Number: 1254 • ACR Convergence 2024

    The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

    Robert Spiera1, Paul Dolin2, Anat Shavit2, Jennifer Rowell3, Chris Edmonds4, Josefine Persson5, Danuta Kielar6, Daniel Mascia7, James Siddall7, Tia Pennant7, Fritha Hennessy7 and Stephanie Y. Chen8, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Market Access and Pricing, AstraZeneca, Gothenburg, Sweden, 6Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 7Adelphi Real World, Bollington, United Kingdom, 8BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody-associated vasculitis that confers significant disease burden. This real-world study described the impact of…
  • Abstract Number: 1387 • ACR Convergence 2024

    Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study

    Andrey Karateev1, Sofia Kuzkina2, Galym Togizbayev3, Elena Polishuk1, Ekaterina Filatova1, Vera Amirdzhanova1, Victoria Khlaboshchina1, Natalia Lapkina4, Andrey Baranov4 and Alexander Lila5, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2R-Pharm, Moscow, Russia, 3Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, 4Yaroslavl State Medical University, Yaroslavl, Russia, 5Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

    Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…
  • Abstract Number: 1943 • ACR Convergence 2024

    Virtual Rheumatology in the Real World: Use of Telemonitoring to Optimize the Management of Patients with Rheumatoid Arthritis

    Maria Di Cicco1, Elisa Verduci1, Marina Muscarà1, Laura Belloli1, Antonella Adinolfi1, Cinzia Casu1, Davide Filippini1, Federica Filippini2, Maria Chiara Gerardi1, Martina Schettino1, Nicola Ughi3 and Oscar Massimiliano Epis1, 1Niguarda Hospital, Milan, Milan, Italy, 2Bicocca University, Milan, Italy, 3Niguarda Hospital, Milan, Mila, Italy

    Background/Purpose: The burden of chronic musculoskeletal disease is increasing worldwide, with a high demand for innovative approaches to deliver effective, feasible and cost-effective access to…
  • Abstract Number: 2170 • ACR Convergence 2024

    Preliminary Evaluation of a Patient-Reported Version for the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): The Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAQ)

    Patti Katz1, Amanda Eudy2, Sarah Patterson3, Jennifer Rogers4, David Pisetsky5, Megan Clowse6 and Maria Dall'Era7, 1UCSF, San Rafael, CA, 2Duke University, Raleigh, NC, 3University of California San Francisco, San Francisco, CA, 4Duke University, Durham, 5Duke University Medical Center, Durham, NC, 6Duke University, Chapel Hill, NC, 7UCSF, Corte Madera, CA

    Background/Purpose: Much of the evidence demonstrating the impact of systemic lupus erythematosus (SLE) on patients’ lives, functioning, and quality of life has come from observational…
  • Abstract Number: 2455 • ACR Convergence 2024

    Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)

    Jonathan Li1, Paulina Horvei2, Franziksa Rosser3, Kirsten Rose-Felker4, Vibha Sood5, Adam Olson6, Vickie Vandergrift7, Nicole Hogue2, Lauren Farver8, Devin Mcguire9, Haley Havrilla7, Jessie Alexander10, Shawna McIntyre2, Paul Szabolcs2 and Kathryn Torok11, 1Division of Rheumatology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 2Division of Blood and Marrow Transplantation and Cellular Therapies, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 3Division of Pulmonology Medicine, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 4Division of Cardiology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 5Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 6Department of Radiation Oncology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 7Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 8Department of Physical Therapy, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 9Pediatric Behavioral Health, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 10Pediatric Bone Marrow Transplant and Cellular Therapies, Stanford Children's Hospital, Palo Alto, CA, USA, Pittsburgh, 11Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a systemic autoimmune disease characterized by vasculopathy and multiorgan fibrosis leading to significant morbidity and early mortality.  Autologous stem…
  • Abstract Number: L06 • ACR Convergence 2023

    Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)

    Kathryn Torok1, Paulina Horvei1, Franziska Rosser1, Kirsten Rose-felker2, Vibha Sood2, Adam Olsen2, Nicole Hogue2, Vickie Vandergrift2, Lauren Farver2, Devin Mcguire2, Jonathan Li3, Haley Havrilla2, Jessie Alexander4, Shawna McIntyre2 and Paul Szabolcs1, 1University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Stanford Children's Hospital, Palo Alto, CA

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
  • Abstract Number: 0343 • ACR Convergence 2023

    Sjögren’s Disease Patient Experiences with Dry Mouth and Content Validity of the Xerostomia Inventory

    Denise Kruzikas1, Ann Eldred2, Shelly Kafka3, Janet Church4, Katherine Hammitt4, Patricia Koochaki5, Christina O'Donnell6 and William Thomson7, 1AbbVie, Inc., North Chicago, IL, 2AbbVie, Inc., Lake Bluff, IL, 3AbbVie, Inc., Norristown, PA, 4Sjögren’s Foundation, Reston, VA, 5ICON Clinical Research LLC, Raleigh, NC, 6ICON plc, Raleigh, NC, 7Department of Oral Sciences, Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand

    Background/Purpose: Xerostomia (dry mouth) is one of the most prevalent symptoms experienced by patients with Sjögren’s Disease (SJD). The Xerostomia Inventory (XI) is a 11-item…
  • Abstract Number: 0507 • ACR Convergence 2023

    The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis

    Antoni Chan and NiSoe Nwe, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom

    Background/Purpose: Patient-reported outcome measures (PROMs) are important tools for evaluating disease activity, functional status, and quality of life in patients with psoriatic arthritis (PsA). The…
  • Abstract Number: 1032 • ACR Convergence 2023

    “Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)

    Bryanna Mantilla1, K Wysham2, Jean liew3 and Grant Hughes1, 1University of Washington, Seattle, WA, 2VA Puget Sound/University of Washington, Seattle, WA, 3Boston University, Boston, MA

    Background/Purpose: Axial spondyloarthritis (axSpA) can result in significant morbidity. Existing studies suggest functional impairment and inflammation may be worse in Black and Latine patients. However,…
  • Abstract Number: 1268 • ACR Convergence 2023

    Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup

    Tetsuji Sawada1, Susumu Nishiyama2, Shohei Yamashita3, Toshihiro Matsui4 and Shigeto Tohma5, 1Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, 2Kurashiki Medical Center, Kurashiki, Japan, 3Tokyo Medical University Hospital, Shinjuku, Japan, 4NHO Sagamihara National Hospital, Kanagawa, Japan, 5NHO Tokyo National Hospital, Dallas, TX

    Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) regarding the disease activity of rheumatoid arthritis (RA) can be divided into three…
  • Abstract Number: 1425 • ACR Convergence 2023

    Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis

    Dafna Gladman1, Peter Nash2, Philip J. Mease3, Oliver FitzGerald4, Karim R. Masri5, Stephanie Duench6 and Mary Jane Cadatal7, 1Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2School of Medicine, Griffith University, Brisbane, Australia, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 4Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 5Pfizer Inc., Collegeville, PA, 6Pfizer Inc., New York, NY, 7Pfizer Inc., Manila, Philippines

    Background/Purpose: Patients (pts) with PsA and an inadequate response (IR) to conventional synthetic DMARDs are routinely treated with TNF inhibitors (TNFi).1,2 Intolerance/IR to TNFi may…
  • Abstract Number: 1955 • ACR Convergence 2023

    Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies

    Didem Saygin1, Dana Direnzo2, Joost Raaphorst3, Jin Kyun Park4, Ingrid de Groot5, Clifton Bingham6, Ingrid Lundberg7, Malin Regardt8, catherine Sarver9, Marianne de Visser10, lara maxwell11, Dorcas Beaton12, Ju Yeon Kim13, Merrilee Needham14, Helene Alexanderson15, Lisa Christopher-Stine6 and Christopher Mecoli16, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pennsylvania, Bala Cynwyd, PA, 3Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 4Seoul National University Hospital and College of Medicine, Seoul, South Korea, 5N/A, Amsterdam, Netherlands, 6Johns Hopkins University, Baltimore, MD, 7Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, 8Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 9N/A, Baltimore, MD, 10University of Amsterdam, Amsterdam, Netherlands, 11University of Ottawa, Ottawa, ON, Canada, 12Institute for Work & Health, Toronto, ON, Canada, 13Seoul National University Hospital, Seoul, South Korea, 14IIID Murdoch University and University of Notre Dame, Perth, Australia, 15Karolinska Institutet, Stockholm, Sweden, 16Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Patient reported outcome measures (PROMs) are critical in assessing clinical outcomes. There is a paucity of PROMs for use in patients with adult idiopathic…
  • Abstract Number: 2194 • ACR Convergence 2023

    Association of Self-perceived Oral Health Status with ESSPRI Reported by Sjögren’s Syndrome Patients

    Oscar E. Alvarez-González1, Hector Guerra2, Elena A. Quintana-Aguilar2, Sandra P. Arroyo-Sánchez2, Jesus S. Cortez-Gutierrez2, Jesus Alberto Cardenas-De la Garza3, Francisco J. Torres-Quintanilla4, Janett Riega-Torres5, Cassandra Michele Skinner-Taylor5 and Dionicio A. Galarza-Delgado6, 1Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, 5Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 6Hospital Universitario UANL, Monterrey, Mexico

    Background/Purpose: Salivary gland hypofunction, manifested as xerostomia in Sjögren's syndrome (SS), causes dental, language, and nutritional problems, leading to a detriment in oral health. The…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology